Ruxience®▼

REFERENCES

  1. RUXIENCE® Summary of Product Characteristics. 
  2. Data on file. Rituximab clinical overview. Pfizer Inc.
  3. Yin D, Becker J-C, Melia LA. A Phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in subjects with active rheumatoid arthritis with active disease in TNF failures (REFLECTIONS B328-01). Poster FRI0309 presented at: European League Against Rheumatism (EULAR) 2014 Annual Congress; June 11-14, 2014; Paris, France. 
  4. Ryan AM, Sokolowski SA, Ng C-K, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®). Toxicol Pathol. 2014;42(7):1069-1081. 
  5. Karnik S, Thompson MS, DeGruttola H, et al. Characterization and comparison of PF-05280586, a proposed rituximab biosimilar, to the licensed product. Poster M1038 presented at: American Association of Pharmaceutical Scientists-National Biotech Conference; May 20-22, 2013; San Diego, CA. 
  6. Data on file. Pfizer oncology strategy and pipeline. Pfizer Inc.
  7. RETACRIT® Summary of Product Characteristics. 
  8. TRAZIMERA® Summary of Product Characteristics. 
  9. NIVESTIM® Summary of Product Characteristics.
  10. ZIRABEV® Summary of Product Characteristics.

 

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SPC for how to report adverse reactions.

Legal Category: POM S1A

 

 

 

 

 

 

 

 

 

 

 

 
 
 
 
 
 
PP-RIT-IRL-0003. Preparation Date: July 2021.